Cure My Disease

Don't miss your cure!

 Log in / Sign up

WEGOVY weight loss study aims to predict who benefits most

NCT ID NCT05897398

Completed Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study followed 1100 adults with severe obesity who took WEGOVY (semaglutide) for 12 months. Researchers collected data on weight, eating habits, and blood markers to see how the drug worked in different groups. The goal is to use this information, along with artificial intelligence, to identify which patients are most likely to lose significant weight. This is an observational study, so it looks at real-world outcomes rather than testing a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
WEGOVY (semaglutide)
What this could lead to
If successful, this study could help doctors predict which patients with severe obesity will lose the most weight with WEGOVY, leading to more personalized treatment.
What could go wrong
This is an observational study, not a controlled trial, so results may not prove cause and effect. Weight loss varies widely, and the findings may not apply to all obesity types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARIATRIC SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

binge eating disorder Binge-Eating Disorder iatrogenic disease Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BARIATRIC SURGERY BINGE-EATING DISORDER IATROGENIC OBESITY OBESITY PSYCHOTROPIC DRUGS SARCOPENIC OBESITY SYNDROMIC OBESITY

Contacts and locations

Locations

  • Espace Médical Nutrition & Obésité (EMNO) Maison Médicale Valmy

    Dijon, 21000, France

  • Service Endocrinologie Diabète Nutrition Hôpitaux de Brabois - CHU Nancy

    Vandœuvre-lès-Nancy, 54500, France

  • Service Endocrinologie Diabétologie CHU de Grenoble

    La Tronche, 38250, France

  • Service Endocrinologie Diabétologie Maladies Métaboliques CHU François Mitterrand Dijon

    Dijon, 21079, France

  • Service Endocrinologie Diabétologie Nutrition APHP - Hôpital Jean Verdier

    Bondy, 93140, France

  • Service Endocrinologie Diabétologie Nutrition CHU Poitiers

    Poitiers, 86021, France

  • Service Endocrinologie Diabétologie Nutrition CHU de Nantes - Hôpital Guillaume & René Laennec

    Nantes, 44093, France

  • Service Endocrinologie Diabétologie Nutrition Hôpital Lapeyronie - CHU Montpellier

    Montpellier, 34295, France

  • Service Endocrinologie Hôpital Conception - APHM

    Marseille, 13385, France

  • Service Endocrinologie Hôpital Haut Léveque - CHU Bordeaux

    Pessac, 33604, France

  • Service Endocrinologie, Maladies Métaboliques et Nutrition Hôpital Rangueil (CHU Toulouse)

    Toulouse, 31059, France

  • Service Nutrition APHP - GHU Pitié Salpêtrière

    Paris, 75013, France

  • Service Nutrition Diabétologie Endocrinologie APHP - Hôpital Européen Georges-Pompidou (HEGP)

    Paris, 75015, France

  • Service de chirurgie APHP - GHU Nord Hôpital Louis Mourier

    Colombes, 92700, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.